IP Library Granted Patent US 10,683,523
Granted Patent B2
US 10,683,523 · App. 15/101,991 · Granted Jun 16, 2020

Method for preparing a dairy product having a stable content of galacto-oligosaccharide(s)

Inventors: Morten Krog Larsen (Sabro, DK); Jacob Flyvholm Cramer (Højbjerg, DK); Thomas Eisele (Hørning, DK)
Assignee: DuPont Nutrition Biosciences ApS
C12P19/14A23C9/1206A23C9/1307A23L33/135A61K31/702C12Y302/01023A23C2220/202A23V2002/00A23Y2300/25
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,523
App. No.
15/101,991
Granted
Jun 16, 2020
Kind
B2
Abstract

The present invention describes a process for in situ generation of stable GOS in different dairy products by the use of a transgalactosylating β-galactosidase.

Claims (14)

1. A method of treating a galacto-oligosaccharides containing milk-based substrate, wherein said milk-based substrate comprises β-galactosidase wherein said β-galactosidase is Bifidobacterium derived β-galactosidase having transgalactosylating activity, which method comprises the step of heat treating said milk-based substrate at a temperature (T) in the range of 90° C.-130° C. for a period of time of at least x seconds, wherein x is related to the temperature T by: x=153,377,215,802.625 e −20378144T ; to obtain a heat treated dairy product, wherein the variation in content of galacto-oligosaccharides is within 0.4% (w/v) in a period of at least 14 days.

2. The method according to claim 1 , wherein said method before said heat treating step further comprises a step of in situ enzymatic treatment of said milk-based substrate with said β-galactosidase to obtain said galacto-oligosaccharides containing milk-based substrate.

3. The method according to claim 1 , wherein said β-galactosidase has a ratio of transgalactosylation activity above 100%.

4. The method according to claim 1 , wherein said temperature is a temperature in the range of 90° C.-119° C.

5. The method according to claim 1 , wherein said period of time is in the range of 0.01 second to 1300 seconds.

6. The method according to claim 1 , wherein the variation in content of galacto-oligosaccharides is within 0.4% (w/v) in a period of at least 3 weeks.

7. The method according to claim 1 , wherein the amount of galacto-oligosaccharide in said heat treated dairy product is within 0.5 to 10% (w/v).

8. The method according to claim 1 , wherein said dairy product has below 0.0213-LAU/ml of residual β-galactosidase activity.

9. The method according to claim 1 , wherein the variation in content of galacto-oligosaccharide is within 0.25% (w/v) measured over at least 14 days.

10. The method according to claim 1 , wherein said milk-based substrate comprises lactose in an amount of at least 1% (w/v).

11. The method according to claim 1 , wherein the Bifidobacterium derived β-galactosidase is a Bifidobacterium bifidum derived β-galactosidase comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence selected from the group of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; and/or wherein the Bifidobacterium derived β-galactosidase is a polypeptide having the amino acid sequence selected from the group of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and/or wherein the Bifidobacterium derived β-galactosidase is a polypeptide comprising any of the polypeptides selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; and/or wherein the Bifidobacterium derived β-galactosidase is a truncated fragment of any of the polypeptides selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and having a minimum length of 850 amino acid residues.

12. The method according to claim 11 , wherein the Bifidobacterium derived β-galactosidase comprises a polypeptide selected from the group consisting of: a. a polypeptide comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1, wherein said polypeptide consists of at most 980 amino acid residues, b. a polypeptide comprising an amino acid sequence having at least 97% sequence identity with SEQ ID NO: 2, wherein said polypeptide consists of at most 975 amino acid residues, c, a polypeptide comprising an amino acid sequence having at least 96.5% sequence identity with SEQ ID NO: 3, wherein said polypeptide consists of at most 1300 amino acid residues.

13. The method according to claim 11 , wherein the dairy product is drinking milk, sweet milk, condensed milk, whey, or a fermented dairy product.

14. The method according to claim 13 , wherein the dairy product is a fermented dairy product selected from the group consisting of yogurt, buttermilk, Riazhenka, cheese, creme fraiche, quark, Acidophilus milk, Leben, Ayran, Kefir, Sauermilch and fromage frais.

Assignments (2)
CHANGE OF NAME Recorded Feb 6, 2024
From: DUPONT NUTRITION BIOSCIENCES APS
To: INTERNATIONAL N&H DENMARK APS
Reel/Frame 066494/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2018
From: LARSEN, MORTEN KROG; CRAMER, JACOB FLYVHOLM; EISELE, THOMAS
To: DUPONT NUTRITION BIOSCIENCES APS
Reel/Frame 044973/0316 →
Priority Claims (1)
EP 13196704 · Dec 11, 2013 · regional
Continuity (1)
Related Publication 20170073717A1 · Mar 16, 2017